Expertise in
8
conditions

Dr. Anasuya Gunturi

Hematology | Oncology
Lowell General Hospital Cancer Center
295 Varnum Ave, 
Lowell, MA 
Accepting New Patients
Offers Telehealth
17 Years of Experience
Expertise in
8
conditions
Lowell General Hospital Cancer Center
295 Varnum Ave, 
Lowell, MA 

Overview

Anasuya Gunturi is a Hematologist and an Oncologist practicing medicine in Lowell, Massachusetts. She has been practicing medicine for over 17 years.

Dr. Gunturi is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), ALK-Positive Non-Small Cell Lung Cancer, Immune Thrombocytopenic Purpura (ITP), and Adult Immune Thrombocytopenia.

She is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 5 clinical trials. Dr. Gunturi is currently accepting new patients.

Graduate Year

2009

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MA

Hospital Affiliations

Tufts Medical Center
Lowell General Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Lowell General Hospital Cancer Center
295 Varnum Ave, Lowell, MA 01854
Other Locations
Lowell General Hospital Women's Wellness Center
295 Varnum Ave Bldg 3, Lowell, MA 01854
Lowell General Hospital Cancer Center
295 Varnum Ave Fl 3, Lowell, MA 01854

Additional Areas of Focus

Dr. Gunturi has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
View 4 Less Clinical Trials

7 Total Publications

Gastrointestinal bleeding from an arterial-enteric fistula postcoil embolisation of GDA pseudoaneurysm after pancreatico-duodenectomy.
Gastrointestinal bleeding from an arterial-enteric fistula postcoil embolisation of GDA pseudoaneurysm after pancreatico-duodenectomy.
Journal: BMJ case reports
Published: February 24, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (24.5 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma. Dr. Dubois is currently accepting new patients.

Expertise in
24
conditions
Dr. Matthew M. Heeney
Hematology | Oncology
Expertise in
24
conditions
Dr. Matthew M. Heeney
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (24.5 miles away)
877-442-3324
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Matthew Heeney is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Heeney is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Hemoglobinopathy, and Splenectomy. Dr. Heeney is currently accepting new patients.

Expertise in
19
conditions
Dr. Rachel P. Rosovsky
Hematology | Oncology
Expertise in
19
conditions
Dr. Rachel P. Rosovsky
Hematology | Oncology
Referral may be required

Mass General Cancer Center At Newton-Wellesley

2014 Washington St, 
Newton, MA 
 (22.4 miles away)
617-219-1230
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rachel Rosovsky is a Hematologist and an Oncologist practicing medicine in Newton, Massachusetts. Dr. Rosovsky is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Pulmonary Embolism, Venous Thromboembolism (VTE), Deep Vein Thrombosis, Embolectomy, and Thrombectomy. Dr. Rosovsky is currently accepting new patients.

Frequently Asked Questions about Dr. Anasuya Gunturi

How do I make an appointment with Dr. Anasuya Gunturi?

You can book an appointment with Dr. Anasuya Gunturi by calling their office at 978-254-0187. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anasuya Gunturi a top-rated expert for Mantle Cell Lymphoma (MCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anasuya Gunturi is classified as an Advanced expert for Mantle Cell Lymphoma (MCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anasuya Gunturi specialize in?

While Dr. Anasuya Gunturi is a Hematology, they have specific expertise in Mantle Cell Lymphoma (MCL), ALK-Positive Non-Small Cell Lung Cancer, and Immune Thrombocytopenic Purpura (ITP). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Anasuya Gunturi participate in research or clinical trials?

Yes. Dr. Anasuya Gunturi has published 7 articles and abstracts on conditions like Mantle Cell Lymphoma (MCL). You can view a list of Dr. Anasuya Gunturi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anasuya Gunturi accept my insurance?

Dr. Anasuya Gunturi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 978-254-0187 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gunturi's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 46 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile